Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VORIGENPHARM: Voriconazole Preemptive Genotyping Strategy
NCT04238884Phase 4Unknown
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- Jan 2020
- Primary completion
- Jan 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of voriconazole in aspergillosis (2 arms), sponsored by Hospital La Paz Institute for Health Research. Primary endpoint: Serum voriconazole concentration at 5 days. Status: unknown.
02
Drugs
voriconazole
03
Conditions
aspergillosis
Beyond the preview
Go deeper on NCT04238884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238884.